- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07655817
Oral Versus Intravenous Magnesium on Emergence Delirium
Effect of Oral Versus Intravenous Magnesium on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Two-Center, Randomized, Double-Blind, Placebo-Controlled Study
Visão geral do estudo
Status
Descrição detalhada
Magnesium is a non-anesthetic N-methyl-D-aspartate receptor antagonist, which is as an anesthetic- and analgesic-sparing medication, with controversial clinical effectiveness.
Regarding its use as a preventive measure against emergence delirium in children, only intraoperative IV route was studied and the results of previous reports were inconsistent.
Oral magnesium syrup is a common drug used for enzyme activation, muscle and bone health, with calming effect and central nervous system supporting value.
In this novel study, we will compare the use of magnesium via two different routes, either oral route before surgery or IV route after sevoflurane induction, regarding their preventive value against the occurrence of emergence delirium in children undergoing adenotonsillectomy. Given the fact that preoperative anxiety and parent separation are predictors for emergence delirium, the calming effect, sleep promoting value of oral magnesium that may be obtained before anesthetic induction together with its peri-operative analgesic effects may suggest a prophylactic benefit against emergence delirium. So, we hypothesize that either oral or IV magnesium therapy may decrease the incidence of emergence delirium in this setting.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Osama M Rehab, MD
- Número de telefone: 002 +201095210806
- E-mail: osamarehab@med.tanta.edu.eg
Locais de estudo
-
-
Gharbia Governorate
-
Tanta, Gharbia Governorate, Egito, 31527
- Recrutamento
- Tanta University Hospitals
-
Contato:
- Osama M Rehab, MD
- Número de telefone: 002 +201095210806
- E-mail: osamarehab@med.tanta.edu.eg
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Children aged 4 to 7 years
- American Society of Anesthesiologist (ASA) Status I or II
- Planned for an adenotonsillectomy procedure under sevoflurane general anesthesia.
Exclusion Criteria:
- Parents declined to participate in the trial
- Behavioral changes, neurological or psychiatric problems
- Anticonvulsant or sedative drugs
- Physical or developmental abnormalities
- Allergies to magnesium
- cardiovascular, renal, bone, or gastrointestinal diseases.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Oral magnesium group
cases will receive preoperative oral magnesium dose of 150 mg at two hours before surgery.
|
cases will receive preoperative oral magnesium dose of 150 mg (10 ml of Magnesium Glycinate Liquid Trace syrup) at two hours before surgery, and will receive intraoperative IV (10 ml) of saline 0.9% over 10 minutes (1ml/min) after induction of anesthesia and before the start of surgical procedure.
|
|
Experimental: Intravenous magnesium group
cases will receive intraoperative IV magnesium sulfate dose of 30 mg/kg (diluted in saline to a total volume of 10 ml) over 10 minutes (1ml/min) after induction of anesthesia and before the start of surgical procedure.
|
cases will receive oral lemon juice (10 ml) at two hours before surgery, and will receive intraoperative IV magnesium sulfate dose of 30 mg/kg (diluted in saline to a total volume of 10 ml) over 10 minutes (1ml/min) after induction of anesthesia and before the start of surgical procedure.
|
|
Comparador de Placebo: Control group
cases will receive oral lemon juice (10 ml) at two hours before surgery and will receive intraoperative IV (10 ml) of saline 0.9% over 10 minutes (1ml/min) after induction of anesthesia and before the start of surgical procedure.
|
cases will receive oral lemon juice (10 ml) at two hours before surgery and will receive intraoperative IV (10 ml) of saline 0.9% over 10 minutes (1ml/min) after induction of anesthesia and before the start of surgical procedure.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of emergence delirium
Prazo: Up to 1 hour after surgery.
|
Pediatric Anesthesia Emergence Delirium scale will be used and a score >12 together with a Delirium-specific score ≥ 9 will be considered a diagnostic endpoint for the development of delirium.
it will be assessed on arrival to the post-anesthesia care unit and every 15 min thereafter for 1 hour
|
Up to 1 hour after surgery.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Severity of emergence delirium
Prazo: Up to 1 hour after surgery.
|
Pediatric Anesthesia Emergence Delirium scale scores will be recorded
|
Up to 1 hour after surgery.
|
|
Postoperative pain
Prazo: Up to 1 hour after surgery.
|
the Face, Legs, Activity, Cry and Consolability (FLACC) scale will assess the pain degree at post-anesthesia care unit arrival and every 0.25 hour for 1 hour after surgery.
A FLACC score of at least 4 will be treated with 0.5mcg/kg of IV fentanyl
|
Up to 1 hour after surgery.
|
|
Parental separation anxiety
Prazo: Perioperative
|
It will be assessed at the time of taking the child to the operating theater by the attending anesthesiologist using the Parent Separation Anxiety Scale.
It ranges from one to four where one refers to easy separation; two equals whimpers; three denotes that the child cries and cannot be easily reassured, but not clinging to parents; and 4 signifies crying and clinging to parents.
A score of 1 or 2 was considered as 'acceptable' separation
|
Perioperative
|
|
Mask acceptance
Prazo: Perioperative
|
The ease of mask acceptance will be graded using the Mask Acceptance Score at the time of induction of general anesthesia with sevoflurane.
It is a 4-point scale: 1 = excellent (unafraid, accepts mask readily); 2 = good (slight fear of mask, easily reassured); 3 = fair (moderate fear of mask, not calmed with reassurance); and 4 = poor (terrified, combative and crying).
A score of 1 or 2 was considered 'satisfactory' mask acceptance.
|
Perioperative
|
|
The total dose of rescue propofol
Prazo: Up to 1 hour after surgery.
|
Parental contact will be initiated as the first line management of delirium.
If the PAED score remains at least 13 with a Delirium-specific score at least 9 despite parental contact, 1 mg/kg IV propofol will be administered.
This dose will be repeated after 15 min if the child still agitated.
The total dose of rescue propofol will be recorded.
|
Up to 1 hour after surgery.
|
|
The total dose of rescue fentanyl
Prazo: Up to 1 hour after surgery.
|
A FLACC score of at least 4 will be treated with 0.5mcg/kg of IV fentanyl.
This dose will be repeated after 15 min if the child still in pain.
The total dose of rescue fentanyl will be recorded
|
Up to 1 hour after surgery.
|
|
Extubation time
Prazo: End of surgery.
|
At the end of surgery, the trachea will be extubated with the patient in the lateral position after confirmation that the gag reflex returned
|
End of surgery.
|
|
Negative behavior changes
Prazo: 24 hours after surgery.
|
Post Hospitalization Behavior Questionnaire will be used to evaluate the child's baseline behavior before anesthesia and any negative behavioral changes at 24 hours postoperatively.
Significant negative behavioral changes will be defined as ≥ 7 negative changes on the Post Hospitalization Behavior Questionnaire items in comparison with the pre-anesthesia baseline values.
|
24 hours after surgery.
|
|
Side effects
Prazo: Up to 1 hour after surgery.
|
Postoperative nausea and vomiting , hypotension, bradycardia will be recorded
|
Up to 1 hour after surgery.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Complicações pós-operatórias
- Processos Patológicos
- Confusão
- Manifestações Neurocomportamentais
- Distúrbios Neurocognitivos
- Delírio
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Delírio de emergência
- Compostos de enxofre
- Produtos químicos inorgânicos
- Ácidos de enxofre
- Sulfatos
- Ácidos sulfúrico
- Compostos de magnésio
- Sulfato de Magnésio
- diglicinato de magnésio
Outros números de identificação do estudo
- 36265PR76/5/26
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .